Pharmaceutical

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s fibroblast platform.

Oct 10, 2024 - 04:00
MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s fibroblast platform.
Read the original article

Tags:

Previous Article

Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets’

Next Article

Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biocytogen and Radiance partner for bispecific antibody-drug conjugate

Biocytogen and Radiance partner for bispecific antibody...

Jan 9, 2024

STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion

STAT+: Bristol Myers to buy cancer player Mirati for mo...

Oct 8, 2023

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT+: AbbVie purchases neuroscience developer Cerevel ...

Dec 7, 2023